05.06 Specific t cell and b cell distributions characterise subgroups of patients with primary sjögren’s syndrome and are associated with disease activity and pro-inflammatory cytokine expression

2017 ◽  
Author(s):  
Lucas Le Lann ◽  
Quentin Simon ◽  
Christophe Jamin ◽  
Divi Cornec ◽  
Maria-Oriette Borghi ◽  
...  
Keyword(s):  
T Cell ◽  
Disease Activity ◽  
B Cell ◽  
Inflammatory Cytokine ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Cytokine Expression ◽  
Primary Sjögren’S Syndrome ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome

scholarly journals Expression of TLR10 in B cells Correlates With Primary Sjögren’s Syndrome Progression

2021 ◽  
Author(s):  
Nannan Lai ◽  
YiChao Qian ◽  
Yilin Wu ◽  
Xi Jiang ◽  
Honghua Sun ◽  
...  
Keyword(s):  
B Cells ◽  
Disease Activity ◽  
B Cell ◽  
High Activity ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Memory B Cells ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome

Abstract Primary Sjögren’s Syndrome (pSS) is considered a B cell-mediated disease, yet the precise role of B cells in the pathogenesis is not fully understood. Toll-like receptor 10 (TLR10) is highly expressed in human B cells, indicating that TLR10 probably plays a vital role in regulating B cell function as well as B cell-related diseases. However, the biology of TLR10 in pSS was rarely researched. Here, we examined the TLR10 expression in peripheral B cell subsets isolated from both pSS patients and healthy controls (HCs) and further analyzed the correlations between TLR10 expression and disease activity. We observed that TLR10 expression in peripheral total CD19+ B cells, naïve B cells (CD19+CD27-IgD+) and switched memory B cells (CD19+CD27+IgD-) was significantly increased in low-activity pSS patients as compared with HCs and high-activity pSS patients. TLR10 expression in total and switched memory B cells in pSS patients was significantly negatively correlated with serum levels of anti-SSA antibody and B cell activating factor of TNF family (BAFF). As compared with the TLR10 low-, the TLR10 high-expressed pSS patients presented with reduced switched memory B cells. Moreover, a much lower proportion of high-activity pSS patients was observed in TLR10 high- as compared to low-expressed patients. Our study concluded that TLR10 expression in peripheral total and switched memory B is negatively correlated with pSS disease activity, suggesting that TLR10 might suppress pSS progression via inhibiting the B cell class switch recombination. These results should contribute to the diagnosis and treatment of pSS.

scholarly journals B-cell activity markers are associated with different disease activity domains in primary Sjögren’s syndrome

Rheumatology ◽  
2018 ◽  
Vol 57 (7) ◽  
pp. 1222-1227 ◽  
Author(s):  
Katherine James ◽  
Chimwemwe Chipeta ◽  
Antony Parker ◽  
Stephen Harding ◽  
Simon J Cockell ◽  
...  
Keyword(s):  
Disease Activity ◽  
B Cell ◽  
Sjögren's Syndrome ◽  
Cell Activity ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

scholarly journals The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren’s Syndrome

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
Linbo Li ◽  
Jing He ◽  
Lei Zhu ◽  
Yuqin Yang ◽  
Yuebo Jin ◽  
...  
Keyword(s):  
T Cell ◽  
Disease Activity ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Cell Populations ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

Objective. Th17 cells have been demonstrated to play an important role in the onset and development of primary Sjögren’s syndrome (pSS). In this study, we evaluated the expansion and clinical significance of circulating CD4+CD161+ T cell and its “effector” (CD4+CD25−CD161+ T cell) and “regulatory” (CD4+CD25+CD161+ T cell) subpopulations.Methods. Fifty-eight pSS patients and 16 healthy controls (HCs) were recruited in our study. The cell populations and intracellular IL-17 expression were analyzed by flow cytometry. The disease activity was evaluated by the EULAR-SS Disease Activity Index (ESSDAI). Autoantibodies were measured by ELISA or indirect immunofluorescence assay.Results. The CD161+ T cell fractions showed higher proportions of IL-17-producing cells. The frequencies of the overall CD4+CD161+ T cell population and its effector subset were positively correlated with disease activity parameters and more severe disease manifestations. A significant elevation of the CD4+CD25+CD161+ T cell subpopulation was observed in the peripheral blood of pSS patients compared to HCs and this subset showed decreased regulatory functions compared with the CD4+CD25+CD161− population.Conclusion. Circulating CD4+CD161+ T cell populations associated with pSS disease activity and severity. These cells might be involved in the development of pSS and could be potential therapeutic targets in the treatment of pSS.

Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome

2017 ◽  
Vol 69 (9) ◽  
pp. 1850-1861 ◽  
Author(s):  
Gwenny M. Verstappen ◽  
Petra M. Meiners ◽  
Odilia B. J. Corneth ◽  
Annie Visser ◽  
Suzanne Arends ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Primary Sjogren’S Syndrome ◽  
Helper T Cell ◽  
Primary Sjögren's Syndrome ◽  
Follicular Helper ◽  
Follicular Helper T Cell

scholarly journals Clinical features and risk factors of Raynaud’s phenomenon in primary Sjögren’s syndrome

2021 ◽  
Author(s):  
Wei Lin ◽  
Zhifei Xin ◽  
Xiaoran Ning ◽  
Yang Li ◽  
Xiuying Ren ◽  
...  
Keyword(s):  
Risk Factors ◽  
Disease Activity ◽  
Raynaud’S Phenomenon ◽  
Sjogren’S Syndrome ◽  
Raynaud's Phenomenon ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Lung Involvement ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome

Abstract Objective The aim at the current study was to investigate the clinical characteristics and risk factors of Raynaud’s phenomenon (RP) in patients with primary Sjögren’s syndrome (pSS). Methods Retrospective analysis of the medical records of 333 new-onset pSS patients was performed. Demographic, clinical, and serological data were compared between individuals with and without RP. Logistic regression analysis was used to identify risk factors. Results RP was present in 11.41% of the pSS patients. pSS-RP patients were younger (49.74±14.56 years vs. 54.46±13.20 years, p=0.04) and exhibited higher disease activity (11 [5.75–15] vs. 7 [4–12], p=0.03) than those without. The prevalence of lung involvement was significantly higher in pSS patients with RP (60.53% vs. 17.29%; p<0.001). A significantly higher proportion of patients with pSS-RP tested positive about antinuclear (ANA), anti-RNP, and anti-centromere antibodies (ACA) compared to those without (p=0.003, <0.001, and 0.01, respectively). Multivariate analysis identified lung involvement (odds ratio [OR]=8.81, 95% confidence interval [CI] 2.02–38.47; p=0.04), anti-RNP positive status (OR=79.41, 95% CI 12.57–501.78; p<0.0001), as well as ACA (OR=13.17, 95% CI 2.60–66.72; p=0.002) as prognostic factors for pSS-RP. Conclusion The presence of RP defined a subset of pSS with a unique phenotype, manifesting as increased lung involvement and a higher frequency of anti-RNP antibodies and ACA, as well as greater disease activity. These results suggest that RP has clinical and prognostic value of pSS patients. Further prospective studies with a larger number of subjects are warranted to confirm our findings and assess the prognostic and treatment implications of RP in pSS patients. Key Points• Raynaud’s phenomenon (RP) was present in 38 (11.41%) of 333 patients with primary Sjögren’s syndrome (pSS), with patients with RP exhibiting a younger age and higher disease activity.• The presence of RP indicates a subset of pSS with a unique phenotype, with manifestations including increased lung involvement and a higher frequency of anti-RNP antibodies and anti-centromere antibodies.• Patients with pSS and RP need close follow-up and long-term observation (including assessment of microangiopathy), with specific attention paid to the possible development of clinical features of systemic sclerosis.

Sign in / Sign up

Export Citation Format

Share Document